Research shows that Lacticaseibacillus paracasei 18 (LP18), a beneficial bacteria, significantly reduced colon inflammation and damage in mice with colitis by strengthening the intestinal barrier and calming the immune system’s inflammatory response. According to Gram Research analysis, treated mice showed improved weight maintenance, reduced colon shortening, and enhanced expression of protective barrier genes compared to untreated mice. While these findings are promising for potential human treatment of ulcerative colitis, human clinical trials are still needed.
Researchers discovered that a specific type of beneficial bacteria called Lacticaseibacillus paracasei 18 (LP18) can help reduce inflammation in the colon and improve gut health. Using advanced laboratory techniques, scientists studied how this bacteria works in mice with colitis, a painful inflammatory bowel disease. According to Gram Research analysis, the bacteria improved the animals’ weight, reduced colon damage, and calmed down the immune system’s inflammatory response. The findings suggest this probiotic could become a new treatment option for people suffering from ulcerative colitis, though human studies are still needed to confirm these promising results.
Key Statistics
A 2026 research study found that mice treated with Lacticaseibacillus paracasei 18 showed significant improvements in body weight loss and colon damage compared to untreated mice with colitis.
According to the 2026 study, LP18 treatment substantially increased expression of five protective genes (Claudin-1, Claudin-2, Claudin-5, ZO-1, and Occludin) that strengthen the intestinal barrier in colitis mice.
The 2026 research demonstrated that LP18 significantly reduced activity in the PI3K/AKT/NF-κB inflammatory signaling pathway, a major driver of immune system inflammation in colitis.
A 2026 analysis revealed that LP18 substantially altered intestinal metabolic profiles, particularly compounds related to tryptophan metabolism, which are linked to improved immune regulation and gut health.
The Quick Take
- What they studied: Whether a specific probiotic bacteria (LP18) could reduce inflammation and heal damage in colons affected by colitis
- Who participated: Laboratory mice with experimentally-induced colitis (inflammatory bowel disease), compared to untreated mice
- Key finding: Mice treated with LP18 showed significant improvement in weight loss, colon damage, and immune system inflammation compared to untreated mice
- What it means for you: This research suggests LP18 might become a probiotic treatment for ulcerative colitis in humans, but human clinical trials are needed before it can be recommended as a medical treatment
The Research Details
Scientists induced colitis in laboratory mice using a chemical called dextran sodium sulfate (DSS), which damages the colon lining and causes inflammation similar to human ulcerative colitis. They then treated some mice with the probiotic bacteria LP18 while leaving others untreated as a control group. The researchers used three advanced laboratory techniques to understand how the bacteria worked: they analyzed the gut bacteria composition, measured chemical compounds produced in the intestines, and examined which genes were turned on or off in the colon tissue. This multi-layered approach allowed them to see not just whether the treatment worked, but exactly how it worked at the molecular level.
This research approach is important because it goes beyond simply testing whether a treatment works—it reveals the actual biological mechanisms involved. By combining three different types of analysis (microbiota, metabolites, and gene expression), the researchers could trace a complete pathway from how the bacteria changes the gut environment, to what chemical compounds are produced, to how this ultimately reduces inflammation in the colon. This comprehensive understanding helps scientists design better treatments and predict whether similar bacteria might work for other inflammatory conditions.
This is a well-designed laboratory study published in a peer-reviewed scientific journal. The researchers used multiple complementary analytical techniques, which strengthens their findings. However, this is animal research (mice), not human research, so results may not directly translate to people. The study lacks specific information about sample sizes and statistical significance testing in the abstract, which would be important for fully evaluating the strength of the findings.
What the Results Show
Mice treated with LP18 showed multiple signs of improvement compared to untreated mice with colitis. First, they experienced less body weight loss, which is a key indicator of disease severity in colitis models. Second, their colons were less shortened and damaged—colitis typically causes the colon to shrink, and LP18 treatment reduced this damage. Third, the bacteria improved the expression of genes that maintain the intestinal barrier (the protective lining of the colon), including genes called Claudin-1, Claudin-2, Claudin-5, ZO-1, and Occludin. A stronger intestinal barrier prevents harmful bacteria and toxins from leaking through the colon wall, which is a major problem in ulcerative colitis. These improvements suggest the bacteria works by both strengthening the gut’s physical defenses and reducing inflammation.
The metabolomic analysis revealed that LP18 significantly changed the chemical compounds produced in the intestines, particularly those related to tryptophan metabolism. Tryptophan is an amino acid that plays important roles in immune regulation and gut health. The bacteria also improved the overall diversity and composition of the gut microbiota—essentially restoring a healthier bacterial community. Gene expression analysis showed that LP18 reduced activity in several inflammatory signaling pathways, with the most significant effect on the PI3K/AKT/NF-κB pathway, which is a major driver of inflammation in the immune system. The correlation analysis connected all these findings together, showing that the bacteria that increased in number were directly linked to reduced activity in inflammatory genes.
This research builds on existing knowledge that probiotics can help with inflammatory bowel disease by adding detailed mechanistic information. Previous studies have shown that various probiotics can reduce colitis symptoms, but this study provides a more complete picture of how LP18 specifically works. The focus on tryptophan metabolism and the PI3K/AKT/NF-κB pathway represents a more sophisticated understanding of probiotic mechanisms than earlier research. The multi-omics approach (combining microbiota, metabolite, and gene data) is increasingly common in modern microbiome research and represents an advancement in how scientists study these complex interactions.
This study was conducted entirely in laboratory mice, not humans, so the results may not directly apply to people with ulcerative colitis. The abstract does not specify the exact number of mice used or provide detailed statistical analysis, making it difficult to assess the strength of the findings. The study used an artificial method to induce colitis (chemical treatment) rather than studying naturally occurring disease. Additionally, the research only examined one specific bacterial strain (LP18), so results cannot be generalized to other probiotics. Long-term effects and potential side effects were not evaluated. Human clinical trials would be necessary before LP18 could be recommended as a medical treatment.
The Bottom Line
Based on this research, LP18 shows promise as a potential therapeutic agent for ulcerative colitis, but it is not yet ready for human use. Current evidence level: Preclinical (animal studies only). People with ulcerative colitis should continue following their doctor’s prescribed treatments. Those interested in probiotic therapy should discuss options with their gastroenterologist, as other probiotics have more human research supporting their use. This research may eventually lead to new treatment options, but several years of human clinical trials would be needed first.
This research is most relevant to gastroenterologists and inflammatory bowel disease specialists who are researching new treatments. People with ulcerative colitis or Crohn’s disease may find this encouraging as a potential future therapy, but should not expect LP18 to be available as a treatment soon. Probiotic manufacturers and pharmaceutical companies developing microbiota-based therapies should pay attention to these findings. General readers interested in gut health and probiotics should understand that while this is promising research, it represents early-stage science that requires human validation.
If LP18 moves forward to human clinical trials, it would typically take 5-10 years before it could potentially become available as a medical treatment. Early-phase human trials would likely begin within 2-3 years if funding and regulatory approval are obtained. Benefits in the animal study appeared relatively quickly (within the study period), but human responses may differ and require longer observation periods.
Frequently Asked Questions
Can I take Lacticaseibacillus paracasei 18 to treat my ulcerative colitis?
Not yet—this research is from animal studies only. LP18 shows promise but requires human clinical trials before doctors can recommend it as a treatment. Continue following your doctor’s current treatment plan and discuss any probiotic interest with your gastroenterologist.
How does this probiotic bacteria reduce colon inflammation?
LP18 works through multiple mechanisms: it strengthens the intestinal barrier by increasing protective genes, changes the gut bacterial community composition, alters intestinal chemical compounds (especially tryptophan-related compounds), and reduces activity in inflammatory immune pathways called PI3K/AKT/NF-κB.
When will LP18 be available as a treatment for inflammatory bowel disease?
This is early-stage research, so LP18 is likely 5-10 years away from potential medical use, if it advances through human clinical trials successfully. Researchers would need to conduct multiple phases of human studies before regulatory approval.
Are the results from mice studies applicable to humans with colitis?
Mouse studies provide valuable insights into how treatments work biologically, but results don’t always translate directly to humans. The immune system, gut bacteria, and disease progression differ between species, so human clinical trials are essential to confirm effectiveness and safety.
What other probiotics are currently proven to help with ulcerative colitis?
Several probiotics have more human research support than LP18, including VSL#3 and certain Lactobacillus and Bifidobacterium strains. Ask your gastroenterologist which probiotics have evidence for your specific condition, as individual responses vary significantly.
Want to Apply This Research?
- Users with inflammatory bowel disease could track daily symptom severity (abdominal pain, bowel movement frequency, blood in stool) on a 1-10 scale, along with probiotic supplement use and dietary changes, to monitor patterns and prepare data for discussions with their healthcare provider
- Users could use the app to set reminders for taking probiotic supplements at consistent times daily, log which specific probiotic strains they’re using, and record any symptom changes to identify which products seem most helpful for their individual situation
- Establish a weekly symptom summary that tracks trends over 4-week periods, allowing users to see whether their current probiotic regimen is helping or if adjustments are needed, while maintaining detailed records to share with their gastroenterologist
This research describes laboratory findings in mice and does not represent approved medical treatment for humans. Ulcerative colitis is a serious medical condition requiring professional medical supervision. Do not start, stop, or change any ulcerative colitis treatments without consulting your gastroenterologist or healthcare provider. While probiotics may be beneficial for some people, they are not a substitute for prescribed medications or medical care. Individual responses to probiotics vary significantly. Always discuss probiotic supplements with your doctor before use, especially if you have inflammatory bowel disease or a compromised immune system.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.